This study is comparing two ways to treat severe aortic stenosis (narrowing of the aortic valve) in people who have a bicuspid aortic valve (a heart valve with two flaps instead of the usual three). The two treatments are Transcatheter Aortic Valve Replacement (TAVR), which is a less invasive procedure, and Surgical Aortic Valve Replacement (SAVR), which is open-chest surgery. Both TAVR and SAVR use commercially approved devices. The study aims to see which procedure is safer and more effective. You might be able to join if you are 50 or older, have severe aortic stenosis, and your heart team believes a bioprosthetic valve is suitable for you. The study plans to enroll 1200 participants.

Study design

This is a multicenter, randomized study, meaning you will have an equal chance of receiving either TAVR or SAVR. It plans to enroll 1200 participants.

What's involved

If you qualify, you will be randomized to either TAVR or SAVR. You will have clinic visits at 30 days, one year, and annually for up to 10 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through clinic visits for up to 10 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.